Overexpression of the plasminogen activator inhibitor type-1 in epithelial ovarian cancer

Anticancer Research

Volumn 26, Issue 2 C, 2006, Pages 1683-1689

  Koensgen, Dominique ^a   Mustea, A ^a   Denkert, C ^a   Sun, P M ^a   Lichtenegger, W ^a   Sehouli, J ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Metastasis; Ovarian cancer; PAI 1; Tumor invasion

Indexed keywords

PLASMINOGEN ACTIVATOR INHIBITOR 1;

ADULT; AGED; BENIGN TUMOR; CANCER STAGING; CANCER SURVIVAL; CONFERENCE PAPER; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW UP; FROZEN SECTION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALIGNANT NEOPLASTIC DISEASE; OVARY CANCER; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; PROGNOSIS; PROTEIN ANALYSIS; PROTEIN EXPRESSION;

ADULT; AGED; AGED, 80 AND OVER; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; MULTIVARIATE ANALYSIS; OVARIAN NEOPLASMS; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROGNOSIS; PROSPECTIVE STUDIES;

EID: 33645797766     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (23)

1. Pecorelli S, Benedet J, Beller U, Creasman W, Heintz A and Pettersson F: FIGO Annual Report on the Results of Treatment in Gynaecological Cancer. Oxford, England: Isis Medical Media 6: 1-184, 2001.
2. Andreasen PA, Kjoller L, Christensen L and Duffy MJ: The urokinase-type plasminogen activator system in cancer metastasis: a review. Int J Cancer 72: 1-22, 1997.
3. Nykjaer A, Conese M, Christensen EI, Olson D, Cremona O, Gliemann J and Blasi F: Recycling of the urokinase receptor upon internalization of uPA: Serpin complexes. EMBO J 16: 2610-2620, 1997.
4. Cubellis MV, Wun TC and Blasi F: Receptor-mediated internalization and degradation of urokinase is caused by its specific inhibitor PAI-1. EMBO J 9: 1079-1085, 1990.
5. Berger DH: Plasmin/plasminogen system in colorectal cancer. World J Surg 26: 767-771, 2002.
6. Nekarda H, Siewert J, Schmitt M and Ulm K: Tumor-associated proteolytic factors u-PA and PAI-1 and survival in totally resected gastric cancer. Lancet 343: 117, 1994.
7. Foekens JA, Schmitt M, van Putten WLJ, Peters HA, Bontel-Bal M, Jänicke F and Klijn JGM: Prognostic value of urokinase-type plasminogen activator in 671 primary breast cancer patients. Cancer Res 52: 6101-6105, 1992.
8. Harbeck N, Thomsson C, Berger U, Ulm K, Kates R, Höfler H, Jänicke F, Graeff H and Schmitt M: Invasion marker PAI-1 remains a strong prognostic factor after long-term follow-up both for primary breast cancer and following first relapse. Breast Cancer Res Treat 54: 147-157, 1999.
9. Kobayasi H, Fujishiro S and Terao T: Impact of urokinase type plasminogen activator and its inhibitor type 1 on prognosis in cervical cancer of the uterus. Cancer Res 54: 6539-6548, 1994.
10. Jänicke F, Prechtl A, Thommsen C et al: Randomized adjuvant therapy trial in high-risk lymph node-negative breast cancer patients identified by urokinase-type plasminogen activator and plasminogen activator inhibitor type-1. J Natl Cancer Inst 93: 913-920, 2001.
11. Look MP, van Putten WLJ, Duffy MJ et al: Pooled analysis of prognostic impact of u-PA and PAI-1 in 8377 breast cancer patients. J Natl Cancer Inst 94: 116-128, 2002.
12. Chambers SK, Ivins CM and Carangiu ML: Plasminogen activator inhibitor-1 is an independent poor prognostic factor for survival in advanced stage epithelial ovarian cancer patients. Int J Cancer 79: 449-454, 1998.
13. Kuhn W, Schmalfeldt B, Reuning U, Pache L, Berger U, Ulm K, Harbeck N, Spathe K, Dettmar P, Hofler H, Jänicke F, Schmitt M and Graeff H: Prognostic significance of urokinase (uPA) and its inhibitor PAI-1 for survival in advanced ovarian carcinoma stage FIGO IIIc. Br J Cancer 79: 1746-1751, 1999.
14. Tecimer C, Doering DL, Goldsmith LJ, Meyer JS, Abdulhay G and Wittliff JL: Clinical relevance of urokinase-type plasminogen activator, its receptor and inhibitor type 1 in ovarian cancer. Int J Gynecol Cancer 10: 372-381, 2000.
15. Van der Burg MEL, Henzen-Logmans SC, Berns EMJJ, van Putten WLJ, Klijn JGM and Foekens JA: Expression of urokinase-type plasminogen activator (uPA) and its inhibitor PAI-1 in benign, borderline, malignant primary and metastatic ovarian tumors. Int J Cancer (Pred Oncol) 69: 475-479, 1996.
16. Hoffmann G, Pollow K, Weikel W, Strittmacher HJ, Bach J, Schaffrath M, Knapstein P, Melchert F and Follow B: Urokinase and plasminogen activator-inhibitor (PAI-1) status in primary ovarian carcinomas and ovarian metastases compared to benign ovarian tumors as a function of histopathological parameters. Clin Chem Lab Med 37: 47-54, 1999.
17. Remmele W and Stegner HE: Vorschlag zur einheitlichen Definierung eines immunreaktiven scores (IRS) für den immunhistochemischen Östrogenrezeptornachweis (ER-ICA) im Mammakarzinomgewebe. Pathologe 8: 138-140, 1987.
18. Borgfeldt C, Hansson SR, Gustavsson B, Masback A and Casslén B: Dedifferentiation of serous ovarian cancer from cystic to solid tumors is associated with increased expression of mRNA for urokinase plasminogen activator (uPA), its receptor (uPAR) and its inhibitor (PAI-1). Int J Cancer 92: 497-502, 2001.
19. Kuhn W, Pache L, Schmalfeldt B, Dettmar P, Schmitt M, Jänicke F and Graeff H: Urokinase (u-PA) and PAI-1 predict survival in advanced ovarian cancer patients (FIGO III) after radical surgery and platinum-based chemotherapy. Gynecol Oncol 55: 401-409, 1994.
20. Pujade-Lauraine E, Lu H, Mirshahi S, Soria J, Soria C, Bernadou A, Kruithof EKO, Lijnen HR and Burtin P: The plasminogen-activation system in ovarian tumors. Int J Cancer 55: 27-31, 1993.
21. Konecny G, Untch M, Pihan A, Kimmig R, Gropp M, Stieber P, Hepp H, Slamon D and Pegram M: Association of urokinase-type plasminogen activator and its inhibitor with disease progression and prognosis in ovarian cancer. Clin Cancer Res 7: 1743-1749, 2001.
22. Schmalfeldt B, Kuhn W, Reuning U, Pache L, Dettmar P, Schmitt M, Jänicke F, Höfler H and Graeff H: Primary tumor and metastasis in ovarian cancer differ in their content of urokinase-type plasminogen activator, its receptor, and inhibitors types 1 and 2. Cancer Res 55: 3958-3963, 1995.
23. Schmalfeldt B, Prechtel D, Härting K, Späthe K, Rutke S, Konik E, Fridmann R, Berger U, Schmitt M, Kuhn W and Lengyel E: Increased expression of matrix metalloproteinases (MMP)-2, MMP-9, and the urokinase-type plasminogen activator is associated with progression from benign to advanced ovarian cancer. Clin Cancer Res 7: 2396-2404, 2001.